← 프로그램 목록
항체Phase 2Recruiting

Antibody-Drug Conjugates

SOLTI Breast Cancer Research Group

비교

Antibody-Drug Conjugates(SOLTI Breast Cancer Research Group)은 Advanced or Metastatic Solid Tumour 표적 항체로, Metastatic Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: ADC target assessment on CTCs using epitope-independent enrichment. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 31.2% (ClinicalTrials.gov NCT05460273). PK: t½ 7 h. 차별점: novel structural and mechanistic properties.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 12일 (1일 전)PK/독성 2026년 7월 12일 (1일 전)

Advanced or Metastatic Solid Tumour

Metastatic Breast Cancer

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

ADCs) are transforming the therapeutic landscape of solid tumou

metabolism

Linker cleavability, drug-to-antibody ratio, and payload metabolism are identified as

viral vectors can further confine scFv activity to tumors, coupling checkpoint blockade with

novel structural and mechanistic properties

Mechanism of Action

ADC target assessment on CTCs using epitope-independent enrichment

cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects r

payload metabolism are identified as key pharmacological determinants of myelosuppressive and infectious risk

PD-L1 was highly expressed in MDA-MB-231 and HCC1937 but low

resistance to existing therapies

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 60건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2 · Phase 1
  • Status: No longer available · Active, not recruiting · Completed
  • 주요 endpoint: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer · Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status · Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer · Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients) · Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
  • 등록된 결과: ORR 31.2%
  • 핵심: Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung …

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Antibody-Drug Conjugates은 어떤 치료제인가요?
Antibody-Drug Conjugates(SOLTI Breast Cancer Research Group)은 Advanced or Metastatic Solid Tumour 표적 항체로, Metastatic Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Antibody-Drug Conjugates의 임상 단계는?
Antibody-Drug Conjugates의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.